Illumina Inc. (ILMN) Given “Neutral” Rating at BTIG Research
Illumina Inc. (NASDAQ:ILMN)‘s stock had its “neutral” rating reaffirmed by investment analysts at BTIG Research in a research note issued to investors on Wednesday.
Several other research analysts have also issued reports on ILMN. CL King initiated coverage on shares of Illumina in a research note on Tuesday, June 21st. They issued a “buy” rating and a $165.00 target price on the stock. Cantor Fitzgerald reaffirmed a “hold” rating on shares of Illumina in a research note on Wednesday, June 29th. Zacks Investment Research upgraded shares of Illumina from a “sell” rating to a “hold” rating in a research report on Monday, July 4th. Morgan Stanley downgraded shares of Illumina from an “equal weight” rating to an “underweight” rating and cut their price target for the company from $130.00 to $110.00 in a research report on Tuesday, July 5th. Finally, Piper Jaffray Cos. reiterated an “overweight” rating and issued a $161.00 price target on shares of Illumina in a research report on Friday, July 15th. Two investment analysts have rated the stock with a sell rating, fifteen have issued a hold rating, nine have issued a buy rating and one has assigned a strong buy rating to the company’s stock. Illumina presently has a consensus rating of “Hold” and a consensus target price of $158.34.
Shares of Illumina (NASDAQ:ILMN) traded down 2.02% on Wednesday, reaching $136.18. 2,882,037 shares of the company were exchanged. Illumina has a 12 month low of $127.10 and a 12 month high of $196.47. The stock has a 50 day moving average price of $174.01 and a 200-day moving average price of $156.43. The stock has a market capitalization of $19.96 billion, a P/E ratio of 46.64 and a beta of 0.47.
Illumina (NASDAQ:ILMN) last issued its earnings results on Tuesday, July 26th. The life sciences company reported $0.86 earnings per share (EPS) for the quarter, beating the consensus estimate of $0.73 by $0.13. The company had revenue of $600 million for the quarter, compared to analyst estimates of $31.91 million. Illumina had a net margin of 18.73% and a return on equity of 23.69%. The company’s revenue for the quarter was up 11.3% on a year-over-year basis. During the same quarter last year, the firm earned $0.80 EPS. On average, equities analysts expect that Illumina will post $3.53 EPS for the current fiscal year.
In related news, Director Robert S. Epstein sold 300 shares of the business’s stock in a transaction dated Tuesday, September 20th. The stock was sold at an average price of $174.29, for a total value of $52,287.00. Following the completion of the transaction, the director now owns 6,924 shares of the company’s stock, valued at $1,206,783.96. The transaction was disclosed in a legal filing with the SEC, which can be accessed through the SEC website. Also, Director Daniel Bradbury sold 600 shares of the business’s stock in a transaction dated Friday, October 7th. The shares were sold at an average price of $184.36, for a total value of $110,616.00. Following the completion of the transaction, the director now directly owns 17,065 shares of the company’s stock, valued at approximately $3,146,103.40. The disclosure for this sale can be found here. 1.60% of the stock is owned by corporate insiders.
A number of hedge funds and other institutional investors have recently bought and sold shares of the stock. Physicians Financial Services Inc. increased its position in Illumina by 2,121.2% in the second quarter. Physicians Financial Services Inc. now owns 733 shares of the life sciences company’s stock worth $103,000 after buying an additional 700 shares during the period. Northwestern Mutual Wealth Management Co. increased its position in Illumina by 25.0% in the second quarter. Northwestern Mutual Wealth Management Co. now owns 789 shares of the life sciences company’s stock worth $110,000 after buying an additional 158 shares during the period. Fuller & Thaler Asset Management Inc. bought a new position in Illumina during the second quarter worth approximately $112,000. Ropes Wealth Advisors LLC increased its position in Illumina by 72.6% in the second quarter. Ropes Wealth Advisors LLC now owns 863 shares of the life sciences company’s stock worth $121,000 after buying an additional 363 shares during the period. Finally, Checchi Capital Advisers LLC increased its position in Illumina by 2.4% in the second quarter. Checchi Capital Advisers LLC now owns 958 shares of the life sciences company’s stock worth $134,000 after buying an additional 22 shares during the period. 95.22% of the stock is owned by institutional investors and hedge funds.
Illumina Company Profile
Illumina, Inc (Illumina) offers sequencing and array-based solutions for genetic analysis. The Company’s products and services serve customers in a range of markets, enabling the adoption of genomic solutions in research and clinical settings. The Company’s customers include genomic research centers, academic institutions, government laboratories and hospitals, as well as pharmaceutical, biotechnology, agrigenomics and commercial molecular diagnostic laboratories, and consumer genomics companies.
Receive News & Stock Ratings for Illumina Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Illumina Inc. and related stocks with our FREE daily email newsletter.